Gabriele, a 47-year-old Italian national residing in Brescia, bravely opens up about his personal journey with Chronic Thromboembolic Pulmonary Hypertension (CTEPH), aiming to raise crucial awareness within the pulmonary hypertension community. By sharing his experience, he hopes to shed light on this condition and its impact, offering support and insights to those who may be […]
CTEPH Patients can join the support group at this link
Chronic thromboembolic pulmonary hypertension (CTEPH) Facebook support group Read Post »
Pulmonary endarterectomy (PEA) is the recommended first-line treatment for patients with chronic thromboembolic pulmonary hypertension (CTEPH), if they qualify for the procedure. Alternative therapies include balloon pulmonary angioplasty (BPA) or medical therapy. An article by Jared Kaltwasser for the American Journal of Managed Care, dated April 17, 2023, presents the results of a Swedish single
Chronic thromboembolic pulmonary hypertension (CTEPH) is one of the two rare forms of pulmonary hypertension. It is the result of multiple or recurrent blood clots in the lungs. It is within Group 4 of the current official pulmonary hypertension classification. Learn more about CTEPH at this link on the PHA Canada website
The Pulmonary Hypertension Association (PHA) brochure on chronic thromboembolic pulmonary hypertension contains information about diagnosis, treatments and surgical solutions. It can be downloaded from the PHA website at this link
The 4th Baltic Pulmonary Hypertension and Circulation Conference took place in Riga, Latvia on April 21, 2023. It provided an opportunity to hear about the latest developments in the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension from international experts – Prof. Marcin Kurzyna from Poland and Prof. Olivier Sitbon from France, as well as leading experts
4th Baltic Pulmonary Hypertension and Circulation Conference, April 21, 2023 Read Post »
An interesting summary of the key ten take home messages of the ESC/ERS clinical guidelines for the diagnosis and treatment of pulmonary hypertension by six members of the Task Force who developed them (2020-2022). Features a useful infographic. Collaboration with patient associations is recommended in commandment n°10! A pdf version of the article can be
The World Pulmonary Hypertension Symposia (WSPH) series, started in Geneva in 1973, have been held every 5 years since the Evian edition in 1998: Venice 2003, Dana Point 2008, Nice 2013, Nice 2018. The WSPH have become a traditional appointment among the most authoritative pulmonary hypertension scholars worldwide. They have marked the progresses in pulmonary
World Pulmonary Hypertension Symposium: Barcelona, June 29-30/July 1, 2024 Read Post »
RACE is a (completed) phase 3, multicentre, open-label, parallel-group, randomised controlled trial done in 23 French centres of expertise for pulmonary hypertension enrolling treatment-naive patients aged 18–80 years with newly diagnosed, inoperable chronic thromboembolic pulmonary hypertension and pulmonary vascular resistance of more than 320 dyn·s/cm5. A summary of the article is available on The Lancet
What is chronic thromboembolic pulmonary hypertension? The President of PHASSc, the Turkish pulmonary hypertension association, interviews three medical experts for this educational video.
Educational video about chronic thromboembolic pulmonary hypertension by Prof. Dr. Bedrettin Yildizeli from the Marmara University in Turkey, shared by PAHSSc, the Turkish pulmonary hypertension patient association. The video che can be viewed on the PAHSSc YouTube channel at this link
Excellent educational video in French language about chronic thromboembolic pulmonary hypertension, developed by RespiFil. Discusses causes of chronic thromboembolic pulmonary hypertension, symptoms, diagnostic work up, treatments. Features interviews with French PH experts from the French Network of PH (Pulmotension) including Prof. Marc Humbert from the University Hospitals of Paris-Sud Bicêtre, Le Kremlin-Bicêtre (France), and a
A very clear explanation, in simple language and with excellent visuals, about chronic thromboembolic pulmonary hypertension from Respifil The fact sheet can be dowloaded from Respifil’s website at this link
An educational ideo developed by phaware about chronic thromboembolic pulmonary hypertension. The video can be view at this link on the phaware website
PHA Europe organized an event in the EU Parliament on April 26, 2022 for the launch of its “Call to Action on the unmet needs of patients with pulmonary hypertension”. The event was hosted by MEP Istvan Ujhelyi (Hungary) and chaired by Prof. Marc Humbert (ERS President). The Call to Action is a revisit of
In chronic thromboembolic pulmonary hypertension (Group 4 of the classification of the WHO, World Health Organisation) pulmonary hypertension is due to the mechanical obstruction of the pulmonary circulation by thrombi (blood clots) that have progressively accumulated. In this booklet by AIPI, Italian pulmonary patient association you will find information on: Download the AIPI booklet on
